Design, Synthesis, and Biological Evaluation of Estrogen Receptor Antagonist–Drug Bioconjugate for Targeting Breast Cancer Cell

Kinh-Luan Dao, [±]Rupa Sawant, [¥]James A. Hendricks, Victoria Ronga, *Robert N. Hanson, [±]Vladimir Torchilin Department of Chemistry and Chemical Biology, 360 Huntington Blvd, Northeastern University, Boston Massachusetts 02115-50000

Supporting Information

CONTENTS

S1: ¹ H NMR of 2α	pg.3
S2: ¹³ C NMR of 2α	pg.3
S3: ¹ H NMR of 3	pg.4
S4: ¹³ C NMR of 3	pg.4
S5: ¹ H NMR of 4	pg.5
S6: ¹³ C NMR of 4	pg.5
S7: ¹ H NMR of 5	pg.6
S8: ¹³ C NMR of 5	pg.6
S9: ¹ H NMR of 6	pg.7
S10: ¹³ C NMR of 6	- pg.7
S11: ¹ H NMR of 7	pg.8
S12: ¹³ C NMR of 7	pg.8
S13: ¹ H NMR of 8	pg.9

S14: ¹³ C NMR of 8	pg.9
S15: ¹ H NMR of 9	pg.10
S16: ¹³ C NMR of 9	pg.10
S17: ¹ H NMR of 10	pg.11
S18: ¹³ C NMR of 10	pg.11
S19: ¹ H NMR of 11	pg.12
S20: ¹³ C NMR of 11	pg.12
S21: ¹ H NMR of 12	pg.13
S22: ¹³ C NMR of 12	pg.13
S23: ¹ H NMR of 13	pg.14
S24: ¹³ C NMR of 13	pg.14
S25: ¹ H NMR of 15	pg.15
S26: Stacking ¹ H NMR of Alk- Dox 14	pg.16
S27: Stacking ¹ H NMR of AE- Dox conjugate 15	• pg.17
S28: Stacking IR of AE-Dox conjugate 15	pg.18
S29: Cytotoxicity of N_3 -AE (9) and Alk- Dox (14)	pg. 19

*Author to whom correspondence should be addressed: (Prof. Robert Hanson) Email: <u>r.hanson@neu.edu</u>. Tel: 617-373-3313; Fax: 617-373-3879.

*Bioorganic and Organic Chemistry Laboratory, Chemistry and Chemical Biology Department

[±]Center for Pharmaceutical Biotechnology and Nanomedicine, Pharmaceutical Science Department

¥ Abbreviations: estrogen receptor (AE), tetraethylene glycol (TEG), tamoxifen (TAM), doxorubicin (DOX), estradiol (E_2), antiestrogen-doxorubicin hybrid (AE-DOX), antiestrogen-tamoxifen hybrid (AE-TAM), azido-tamoxifen (N_3 -TAM), alkynated-doxorubicin (Ak-DOX), azido-antiestrogen (N_3 -AE).





(2α)



Figure S2: ¹³C NMR of 3,3ethylenedioxy-5(10)-α-epoxyestr-9(11)-ene (2α) **Figure S3**: ¹H NMR of **11β-(4-Hydroxy-phenyl)-estra-4,9-diene-3,17-dione (3)**



Figure S4: ¹³C NMR of 11β-(4-Hydroxy-phenyl)estra-4,9-diene-3,17-dione (3)

9

8

LL 4: phenolic steroid august 21, 2010 nmr400/dao Pulse Sequence: s2pul Solvent: COCl3 Ambient temperature Mercury-40088 "nmr400"

Refactly-nubbs - maraum-Relax.46.4 gr 1.000 sec Pulse 34.6 degrees Acq. time 1.365 sec Width 6002.4 Hz Unth 6002.4 Hz DATA PROCESSING Line broadening 0.2 Hz FT size 18384 Total time 4 min, 59 sec HO

7

6



Figure S5: ¹H NMR of 11β-[4-(2-Dimethylamino-ethoxy)-phenyl]-estra-4,9-diene-3,17-dione (4)



Figure S6: ¹³C NMR of11β-[4-(2-Dimethylamino-ethoxy)-phenyl]-estra-4,9-diene-3,17-dione

Figure S7: ¹H NMR of 3-Acetoxy-11β-[4-(2-dimethylamino-ethoxy)-phenyl]-estra-1,3,5(10)-triene-17-one(5)





Figure S8: ¹³C NMR of 3-Acetoxy-11β-[4-(2-dimethylamino-ethoxy)-phenyl]-estra-1,3,5(10)-triene-17-

Figure S9: ¹H NMR of 11β-[4-(2-Dimethylamino-ethoxy)-phenyl]-estra-1,3,5(10)-triene-3,17β-diol (6)





Figure S10: ¹³C NMR of 11β-[4-(2-Dimethylamino-ethoxy)-phenyl]-estra-1,3,5(10)-triene-3,17β-diol





Figure S12: ¹³C NMR of 11β-[4-(2-methylamino-ethoxy)-phenyl]-estra-1,3,5(10)-triene-3,17β-diol (7)



Figure S13: ¹H NMR of 2-{2-[2-(2-Azido-ethoxy)-ethoxy]-ethyl tosylate (8)





Figure S14: ¹³C NMR of 2-{2-[2-(2-Azido-ethoxy)-ethoxy]-ethyl tosylate (8)

Figure S15: ¹H NMR of 11β-(4-{2-[(2-{2-[2-(2-Azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-methyl-amino]ethoxy}-phenyl)-estra-1,3,5(10)-triene-3,17β-diol (9)



Figure S16: ¹³C NMR of 11β -(4-{2-[(2-{2-[2-(2-Azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-methyl-amino]-ethoxy}-phenyl)-estra-1,3,5(10)-triene-3,17 β -diol (9)

103-77)) LD3-11; N3-11b-AE NU 13C OBSERVE oct 7,2010 nmr400/dao Pulse Sequence: s2pul Solvent: CDCl3 Ambient temperature Mercury-400BB "nmr400" Hona 1se 36.0 degrees q. time 1.311 sec dth 25000.0 Hz
 Width 25000.0 Hz

 38500 reputitions

 38500 reputitions

 08580W reputitions

 08580W reputitions

 08500 reputitions
60 140 100 80 40 20 ppm 180 160 120

Figure S17: ¹H NMR of 2-{2-[2-(2-Prop-2-ynyloxy-ethoxy)-ethoxy]-ethoxy}-ethanol (10)



Figure S18: ¹³C NMR of 2-{2-[2-(2-Prop-2-ynyloxy-ethoxy)-ethoxy]-ethoxy}-ethanol (10)



Figure S19: ¹H NMR of 2-(2-(2-(2-(Prop-2-

ynnyloxy)-ethoxy)-ethoxy)-ethoxy)-ethanol tosylate (11)





Figure S20: ¹³C NMR of 2-(2-(2-(2-(Prop-2-ynnyloxy)-ethoxy)-





Figure S22: ¹³C NMR of Methyl 4-(2-(2-(2-(2-(prop-2-ynyloxy) ethoxy)ethoxy)ethoxy)ethoxybenzoate (12)



Figure S23: ¹H NMR of 4-(2-{2-[2-(2-Prop-2-ynyloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid hydrazide (13)



Figure S24: ¹³C NMR of 134-(2-{2-[2-(2-Prop-2-ynyloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid hydrazide (13)

















Figure S29: Comparing cytotoxicity of modified A) Azido-AE (9), and B)Alk-Dox (14) with their parent compounds treated in MCF-7 (24h)